371766-08-4

Basic information

• Product Name: Isoquinoline-5-boronic acid
• Synonyms: RARECHEM AK VD 0026;5-ISOQUINOLINEBORONIC ACID;5-ISOQUINOLINEBORONIC ACID, HCL;AKOS BRN-0458;ISOQUINOLIN-5-YLBORONIC ACID;ISOQUINOLIN-5-YLBORONIC ACID, HCL;ISOQUINOLIN-5-YLBORONIC ACID HYDROCHLORIDE;ISOQUINOLINE-5-BORONIC ACID
• CAS NO: 371766-08-4
• Molecular Formula: C₉H₈BNO₂
• Molecular Weight: 209.44
• EINECS: -0
• Product Categories: blocks;BoronicAcids;Quinolines;Quinoline&Isoquinoline;Boronic acid;Isoquinoline;Organoborons;Boronic Acids;Boronic Acids and Derivatives;Heteroaryl;Boric Acid| Boric Acid Ester| Potassium Trifluoroborate
• Mol File: 371766-08-4.mol

Chemical Properties

• Melting Point: 204-206
• Boiling Point: 419.1 °C at 760 mmHg
• Flash Point: 207.3 °C
• Appearance: /
• Density: 1.28 g/cm³
• Vapor Pressure: 2.32E-08mmHg at 25°C
• Storage Temp.: Keep Cold
• CAS DataBase Reference: Isoquinoline-5-boronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: Isoquinoline-5-boronic acid(371766-08-4)
• EPA Substance Registry System: Isoquinoline-5-boronic acid(371766-08-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 371766-08-4(Hazardous Substances Data)

Usage

Uses

Isoquinoline-5-boronic acid, HCl

InChI:InChI=1/C9H8BNO2.ClH/c12-10(13)9-3-1-2-7-6-11-5-4-8(7)9;/h1-6,12-13H;1H

Upstream product

• 34784-04-8 5-bromoisoquinoline 
• 121-43-7 Trimethyl borate 
• 5419-55-6 Triisopropyl borate 
• 7732-18-5 water 

Downstream Products

• 852570-79-7 1-amino-3-isoquinolylbenzene 
• 1021915-53-6 6-(isoquinolin-5-yl)-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one 
• 1038867-89-8 3-fluoro-4-(isoquinolin-5-yl)benzenamine 
• 1038867-71-8 1-(2-hydroxy-2-methylpropyl)-N-(4-(5-isoquinolinyl)-3-methylphenyl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1225183-21-0 5-(2-methoxy-6-(propyn-1-yl)phenyl)isoquinoline 
• 1454667-24-3 tert-butyl 4-(2-(isoquinolin-5-yl)-5-(trifluoromethyl)phenyl)-5,6-dihydropyridine-1(2H)-carboxylate 
• 1454666-56-8 5-(2-(1,2,3,6-tetrahydropyridin-4-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide hydrochloride 
• 1454667-64-1 tert-butyl 4-(2-(2-(N-(thiazol-2-yl)sulfamoyl)-1,2,3,4-tetrahydroisoquinolin-5-yl)-5-(trifluoromethyl)phenyl)-5,6-dihydropyridine-1(2H)-carboxylate 
• 1454666-57-9 N-(pyrimidin-4-yl)-5-(2-(1,2,3,6-tetrahydropyridin-4-yl)-4-(trifluoromethyl)phenyl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide 
• 1454667-66-3 tert-butyl 4-(2-(2-(N-(pyrimidin-4-yl)sulfamoyl)-1,2,3,4-tetrahydroisoquinolin-5-yl)-5-(trifluoromethyl)phenyl)-5,6-dihydropyridine-1(2H)-carboxylate 
• 1454666-62-6 N-(5-fluorothiazol-2-yl)-5-(2-(4-methyl-1H-imidazol-1-yl)-4-(trifluoromethyl)phenyl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide 
• 1454667-78-7 5-(2-(4-methyl-1H-imidazol-1-yl)-4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline 
• 1454666-73-9 N-(pyrazin-2-yl)-5-(2-(1,2,3,6-tetrahydropyridin-4-yl)-4-(trifluoromethyl)phenyl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide hydrochloride 
• 1454667-84-5 tert-butyl 4-(2-(2-(N-(pyrazin-2-yl)sulfamoyl)-1,2,3,4-tetrahydroisoquinolin-5-yl)-5-(trifluoromethyl)phenyl)-5,6-dihydropyridine-1(2H)-carboxylate 

Relevant articles and documents

NOVEL PYRIDIN-2(1H)ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF PAIN

The present invention concerns novel pyridin-2(1H)one derivatives, their process of preparation and their use in therapeutics, in particular as agents for treating and/or preventing pain.

Pyridin-2(1H)one derivatives: A possible new class of therapeutics for mechanical allodynia

Mechanical Allodynia (MA), a frequent chronic pain symptom caused by innocuous stimuli, constitutes an unmet medical need, as treatments using analgesics available today are not always effective and can be associated with important side-effects. A series of 3,5-disubstituted pyridin-2(1H)-ones was designed, synthesized and evaluated in vivo toward a rat model of inflammatory MA. We found that the series rapidly and strongly prevented the development of MA. 3-(2-Bromophenyl)-5-(phenylamino)pyridin-2(1H)-one 69, the most active compound of the series, was also able to quickly reverse neuropathic MA in rats. Next, when 69 was evaluated toward a panel of 50 protein kinases (PK) in order to identify its potential biological target(s), we found that 69 is a p38α MAPK inhibitor, a PK known to contribute to pain hypersensitivity in animal models. 3,5-Disubstituted pyridin-2(1H)-ones thus could represent a novel class of analgesic for the treatment of MA.

Synthesis of nonsymmetrical 5-Aryl-2-indolopyrrole derivatives via controlled mono Suzuki-Miyaura cross-coupling on N-Boc-2,5-dibromopyrrole

The first example of mono Suzuki-Miyaura cross-coupling of N-Boc-2,5-dibromopyrrole with a boronic acid (indol-2-ylboronic acid) is reported. The resulting 2-indolyl-5-bromopyrrole derivative was in turn coupled with a variety of aryl- or heteroarylboronic acids thereby providing the corresponding non-symmetrical 2,5-disubstituted pyrroles in good to excellent yields. The tert-butoxycarbonyl (Boc) groups could be easily removed to give the completely deprotected products. Georg Thieme Verlag Stuttgart - New York.

Nicotinamide n-oxide derivatives as vanilloid-1 receptor modulators

The present invention relates to vanilloid receptor modulators of formula (I) wherein X is selected from phenyl, naphthyl, pyridine, quinoline or isoquinoline and Y is optionally substituted phenyl or pyridyl ring, to processes for the preparation thereof

BIARYLCARBOXYARYLAMIDES AS VANILLOID-1 RECEPTOR MODULATORS

The present invention provides compounds of formula (I): wherein A and Z are as defined in the description, along with methods for preparing such derivatives and their use for the treatment of inflammatory diseases such as neuropathic pain.

MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF

A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least one of X1 - X8 is N, and R, Ra, Rb, Rc and Rd are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

Synthesis of quinolyl- and isoquinolyl heteroarylamines using palladium catalyzed suzuki cross-coupling reaction

Quinolyl- and isoquinolylboronic acids are prepared from 5-bromoquinoline and 5-bromoisoquinoline, respectively, via halogen-metal exchange. Suzuki cross-coupling of these compounds with haloheteroarylamine leading to the corresponding heteroarylamine derivatives is described.{A figure is presented}.